FY2024 Earnings Estimate for ACHV Issued By Zacks Small Cap

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Analysts at Zacks Small Cap reduced their FY2024 EPS estimates for Achieve Life Sciences in a note issued to investors on Monday, November 11th. Zacks Small Cap analyst J. Vandermosten now anticipates that the biopharmaceutical company will post earnings of ($1.04) per share for the year, down from their previous estimate of ($0.89). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share.

Achieve Life Sciences (NASDAQ:ACHV) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.10). During the same period in the prior year, the firm posted ($0.34) earnings per share.

Other equities analysts have also issued reports about the stock. Oppenheimer reissued an “outperform” rating and set a $11.00 price target on shares of Achieve Life Sciences in a research report on Thursday, August 15th. Raymond James began coverage on shares of Achieve Life Sciences in a report on Friday, September 27th. They set a “strong-buy” rating and a $20.00 target price for the company.

Achieve Life Sciences Trading Down 2.6 %

Achieve Life Sciences stock opened at $4.53 on Wednesday. The stock has a 50-day moving average price of $4.72 and a 200 day moving average price of $4.77. The company has a market capitalization of $155.79 million, a price-to-earnings ratio of -4.01 and a beta of 1.57. Achieve Life Sciences has a 52 week low of $3.03 and a 52 week high of $5.98. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.31.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Propel Bio Management LLC purchased a new position in shares of Achieve Life Sciences during the 1st quarter valued at approximately $11,149,000. Vanguard Group Inc. grew its position in Achieve Life Sciences by 56.6% during the first quarter. Vanguard Group Inc. now owns 948,441 shares of the biopharmaceutical company’s stock valued at $4,311,000 after buying an additional 342,731 shares during the period. Bank of New York Mellon Corp purchased a new position in Achieve Life Sciences in the second quarter valued at $482,000. Rhumbline Advisers acquired a new position in shares of Achieve Life Sciences in the second quarter worth about $197,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Achieve Life Sciences by 134.2% during the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 14,360 shares in the last quarter. 33.52% of the stock is owned by institutional investors and hedge funds.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.